CXCL10 and dermatomyositis: Both galectin‐9 and CXCL10, as measured in dried blood spots, were capable of discriminating between patients with active juvenile DM and healthy controls (P = 0.0040 and P < 0.0001, respectively) (Figure 4D), with the healthy control subjects having biomarker levels that were similar to those in patients with juvenile DM in remission (Figure 2).